Evaluation of chicken chorioallantoic membrane model for tumor imaging and drug development: Promising findings

Abstract

Background: The chicken chorioallantoic membrane (CAM) model is a potential alternative to the mouse model based on the 3R principles. However, its value for determination of the in vivo behaviors of radiolabeled peptides through positron emission tomography (PET) imaging needed investigation. Herein, the chicken CAM tumor models were established, and their feasibility was evaluated for evaluating the imaging properties of radiolabeled peptides using a ⁶⁸Ga-labeled HER2 affibody.

Methods: Two human breast cancer cell lines were inoculated into chicken CAM and mice, respectively. The tumor-targeting potential and pharmacokinetic profile of a ⁶⁸Ga-labeled affibody, ⁶⁸Ga-MZHER, in both tumor models were also determined.

Results: The tumor-formation time in chicken CAM model was shorter than that of mouse model. The uptake values of human epithelial growth factor receptor-2 (HER2)-positive Bcap37 tumors in chicken CAM and mouse models were 5.36±0.26% ID/g and 5.26±0.43% ID/g at 30min postinjection of ⁶⁸Ga-MZHER, respectively. At the same time points, the uptake values of HER2-negative MDA-MB-231 tumors in the chicken CAM models and mouse models were 1.57±0.15% ID/g and 1.67±0.25% ID/g, respectively. Ex vivo biodistribution confirmed that more radioactivity accumulated in Bcap37 tumors than in MDA-MD-231 tumors in both CAM and mouse models.

Conclusion: In this study, the CAM tumor model was successfully prepared. The chicken CAM model is a novel tool for quickly determining the in vivo properties of radiolabeled peptides targeting biomarkers. It may be beneficial for early monitoring of the therapeutic effect of a new drug through PET imaging with specific peptides.

Keywords

⁶⁸Ga / affibody / chicken embryo CAM / HER2 / PET imaging

References

[1] Moradipoodeh B, Jamalan M, Zeinali M, Fereidoonnezhad M. Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-ZHER2 affibody conjugate. Mol Biol Rep. 2020;47(9):7139-7151.

[2] Harbeck N. Advances in targeting HER2-positive breast cancer. Curr Opin Obstet Gynecol. 2018;30(1):55-59.

[3] Guo X, Zhu H, Zhou N, et al. Noninvasive detection of HER2 expression in gastric cancer by ⁶⁴Cu-NOTA-Trastuzumab in PDX mouse model and in patients. Mol Pharm. 2018;15(11):5174-5182.

[4] Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 2019;11:1758835919833519.

[5] Arciero CA, Guo Y, Jiang R, et al. ER⁺/HER2⁺ breast cancer has different metastatic patterns and better survival than ER⁻/HER2⁺ breast cancer. Clin Breast Cancer. 2019;19(4):236-245.

[6] Liu Y, Wang L, Pan D, et al. PET evaluation of light-induced modulation of microglial activation and GLP-1R expression in depressive rats. Transl Psychiatry. 2021;11(1):26.

[7] Zlatopolskiy BD, Zischler J, Schäfer D, et al. Discovery of 7-[¹⁸F]Fluorotryptophan as a novel positron emission tomography (PET) probe for the visualization of tryptophan metabolism in vivo. J Med Chem. 2018;61(1):189-206. doi:10.1021/acs.jmedchem.7b01245

[8] Alhuseinalkhudhur A, Lindman H, Liss P, et al. Human epidermal growth factor receptor 2-targeting [⁶⁸Ga]Ga-ABY-025 PET/CT predicts early metabolic response in metastatic breast cancer. J Nucl Med. 2023;64(9):1364-1370.

[9] Han J, Chen Y, Zhao Y, et al. Pre-clinical study of the [¹⁸F]AlF-labeled HER2 affibody for non-invasive HER2 detection in gastric cancer. Front Med (Lausanne). 2022;9:803005.

[10] Miladinova D. Molecular imaging of HER2 receptor: targeting HER2 for imaging and therapy in nuclear medicine. Front Mol Biosci. 2023;10:1144817.

[11] Zhou N, Liu C, Guo X, et al. Impact of ⁶⁸Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. Eur J Nucl Med Mol Imaging. 2021;48(1):161-175.

[12] Miao H, Sun Y, Jin Y, Hu X, Song S, Zhang J. Application of a novel ⁶⁸Ga-HER2 affibody PET/CT imaging in breast cancer patients. Front Oncol. 2022;12:894767.

[13] Xu Y, Wang L, Pan D, et al. PET imaging of a ⁶⁸Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients. Br J Radiol. 2019;92(1104):20190425.

[14] Chu P-Y, Koh AP-F, Antony J, Huang RY-J. Applications of the Chick Chorioallantoic membrane as an alternative model for cancer studies. Cells Tissues Organs. 2022;211(2):222-237.

[15] Pinto MT, Ribeiro AS, Conde I, Carvalho R, Paredes J. The chick chorioallantoic membrane model: a new in vivo tool to evaluate breast cancer stem cell activity. Int J Mol Sci. 2020;22(1):334.

[16] Pomraenke M, Bolney R, Winkens T, et al. A novel breast cancer xenograft model using the ostrich Chorioallantoic membrane-a proof of concept. Vet Sci. 2023;10(5):349.

[17] Hilbrig C, Löffler J, Fischer G, et al. Evaluation of the EPR effect in the CAM-model by molecular imaging with MRI and PET using ⁸⁹Zr-labeled HAS. Cancers (Basel). 2023;15(4):1126.

[18] Xu Y, Bai Z, Huang Q, et al. PET of HER2 expression with a novel ¹⁸FAl labeled affibody. J Cancer. 2017;8(7):1170-1178.

[19] Xu Y, Wang L, Pan D, et al. Synthesis of a novel ⁸⁹Zr-labeled HER2 affibody and its application study in tumor PET imaging. EJNMMI Res. 2020;10(1):58.

[20] Veinotte CJ, Dellaire G, Berman JN. Hooking the big one: the potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era. Dis Model Mech. 2014;7(7):745-754.

[21] Jung J, Seol HS, Chang S. The generation and application of patient-derived xenograft model for cancer research. Cancer Res Treat. 2018;50(1):1-10.

[22] Ribatti D. The chick embryo chorioallantoic membrane as a model for tumor biology. Exp Cell Res. 2014;328(2):314-324.

[23] Haller S, Ametamey SM, Schibli R, Müller C. Investigation of the chick embryo as a potential alternative to the mouse for evaluation of radiopharmaceuticals. Nucl Med Biol. 2015;42(3):226-233.

[24] Chen L, Wang S, Feng Y, et al. Utilisation of Chick embryo Chorioallantoic membrane as a model platform for imaging-navigated biomedical research. Cell. 2021;10(2):463.

[25] Sajjad H, Imtiaz S, Noor T, Siddiqui YH, Sajjad A, Zia M. Cancer models in preclinical research: a chronicle review of advancement in effective cancer research. Animal Model Exp Med. 2021;4(2):87-103.

[26] Monzavi SM, Muhammadnejad A, Behfar M, Khorsand AA, Muhammadnejad S, Kajbafzadeh AM. Spontaneous xenogeneic GvHD in Wilms’ tumor patient-derived xenograft models and potential solutions. Animal Model Exp Med. 2022;5(4):389-396.

[27] Warnock G, Turtoi A, Blomme A, et al. In vivo PET/CT in a human glioblastoma chicken chorioallantoic membrane model: a new tool for oncology and radiotracer development. J Nucl Med. 2013;54(10):1782-1788.

[28] Löffler J, Hamp C, Scheidhauer E, et al. Comparison of quantification of target-specific accumulation of [¹⁸F]F-siPSMA-14 in the HET-CAM model and in mice using PET/MRI. Cancers (Basel). 2021;13(16):4007.

[29] Patten LW, Blatchford P, Strand M, Kaizer AM. Assessing the performance of different outcomes for tumor growth studies with animal models. Animal Model Exp Med. 2022;5(3):248-257.

RIGHTS & PERMISSIONS

2024 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.